Pfizer Corporation

Other

Pfizer Products Inc.

Kim F McClure

Michael Anthony Letavic

Mark Anthony Dombroski

Louis Stanley Chupak

Mark Carl Noe

Ellen Ruth Laird

Allyn T Londregan

David W Piotrowski

Kimberly O Cameron

Allen Jacob Duplantier

Ralph P Robinson

Samit Kumar Bhattacharya

Dilinie Fernando

Ralph Pelton Robinson, Jr

Julie Jia Li Hawkins

Daniel W Kung

John Frederick Braganza

Robert Dullea

Paula M Loria

Bruce Maguire

Donna N Petersen

Suvi T M Simila

Etzer Darout

The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

Substituted amide compounds

The present invention provides a compound of Formula (I) or a pharmaceutically salt thereof wherein R, R, Ra, L, Z, Zand Zare as defined herein, that act as Ghrelin antagonists or inverse agonists; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by the antagonism of the Ghrelin receptor.

2,3-dihydro-1H-inden-1-yl-2,7-diazaspiro[3.5] nonane derivatives

The present invention relates to novel triazolo-pyridines of the formula wherein X is &#x3e;CH, &#x3e;NH, sulfur, &#x3e;S&#x2550;O, &#x3e;SOor oxygen; wherein said &#x3e;CHand &#x3e;NH may optionally be substituted with a suitable substituent;

Triazolo-pyridines as anti-inflammatory compounds

The present invention relates to novel triazolo-pyridines of the formula I  wherein Ris fluoro; s is an integer from two to three; Ris (C-C)cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C-C)alkyl, hydroxy, (C-C)alkoxy and (C-C)alkyl-(C&#x2550;O)&#x2014;O&#x2014;; or Ris (C-C)alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C-C)alkyl, hydroxy, (C-C)alkoxy and (C-C)alkyl-(C&#x2550;O)&#x2014;O&#x2014;; with the proviso that said compound of formula I cannot be 6-[4-(2,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; or 6-[4-(3,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Di and trifluoro-triazolo-pyridines anti-inflammatory compounds

The present invention relates to novel triazolo-pyridines of the formula I wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen;

Benzimidazole anti-inflammatory compounds

The present invention relates to novel alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates and methods for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines

This invention relates to a method of treatment for osteoarthritis involving inhibitors of aggrecanase that demonstrate ICs of less than 20 nM and demonstrate differential potency against matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs or reprolysins). This invention also relates to compounds, methods of treatment and composition of Formula I:or a therapeutically acceptable salt thereof, wherein

Selective inhibition of aggrecanase in osteoarthritis treatment

The present invention relates to novel cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines

The present invention relates to novel cycloalkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines

Triazolo-pyridines anti-inflammatory compounds

Benzotriazoles anti-inflammatory compounds

Arylsulfonyl hydroxamic acid derivatives

Hydroxy pipecolate hydroxamic acid derivatives

Arylsulfonylamino hydroxamic acid derivatives

The present invention relates to dioxocyclopentyl hydroxamide derivatives of the formula

Dioxocyclopentyl hydroxamic acids

Growing community of inventors

Mystic, CT, United States of America

Kim F McClure